Recursion Pharmaceuticals, Inc. Class A Common Stock
Here’s whether Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-5.29% over 10 days); RSI 77 — overbought, elevated pullback risk; weak 1-year return of -28.9%; 3-month momentum negative (-19.1%). Currently 47.4% off its 52-week high. Score: -5/7.
RXRX is trading below its 200-day MA ($4.62) — a key warning sign the longer-term trend is under pressure. With an RSI of 76.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -28.9% compares to +35.1% for SPY (trailed the market by 64.0%). The current 47.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.